Metabolic Disorders · Urea Cycle DisorderRegulatory Approvalregulatorymid-term

Lupin's Glycerol Phenylbutyrate Receives FDA Approval Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Lupin12 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:31:29 PM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval status of 'AP' for Lupin's Glycerol Phenylbutyrate indicates a significant step towards market entry, which could reshape competitive dynamics in the metabolic disorders sector. Companies should prepare for potential shifts in market share and competitive strategies as Lupin advances its product. Regulatory context from FDA (FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)) supports the near-term read. Assessment grounded in 25 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and prepare for competitive responses from other companies in the metabolic disorder space. The strongest clinical anchor is Perimenopause-Related Mood and Behavioral Disorders (ClinicalTrials.gov), moderate corpus alignment. In Metabolic Disorders · Urea Cycle Disorder, 6 regulatory and 6 competitive items passed relevance filtering for Lupin.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG) (FDA). Entity match (lupin); Regulatory pathway relevance (nda). The 'AP' status indicates that Lupin is close to receiving final approval, which could influence regulatory strategies for other companies in similar therapeutic areas.

Key Risks

Elevated medium regulatory exposure for Lupin could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Lupin's approval could lead to increased market share in the urea cycle disorder treatment space, prompting competitors to respond strategically to maintain their positions.
Portfolio teams should assess the potential market impact and prepare for competitive responses from other companies in the metabolic disorder space.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval decision and subsequent market entry timelines for Glycerol Phenylbutyrate.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GLYCEROL PHENYLBUTYRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Perimenopause-Related Mood and Behavioral Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
International Registry for TRPM3-associated Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Sandoz Receives FDA Approval for Liraglutide ANDA212972
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Gut Proteobacteria glycine metabolism regulates neuroplasticity, motivation, and reinstatement of cocaine self-administration in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Lupin
metabolic disorder market

Commercial impact

medium

Lupin's approval could lead to increased market share in the urea cycle disorder treatment space, prompting competitors to respond strategically to maintain their positions.

Regulatory impact

medium

The 'AP' status indicates that Lupin is close to receiving final approval, which could influence regulatory strategies for other companies in similar therapeutic areas.

What to watch

Monitor for the final approval decision and subsequent market entry timelines for Glycerol Phenylbutyrate.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.